Abstract
New diagnostic methods and treatments have significantly decreased the mortality rates of cancer patients, but further improvements are warranted based on the identification of novel tumor-promoting molecules that can serve as therapeutic targets. The macrophage migration inhibitory factor (MIF) family of cytokines, comprising MIF and DDT (also known as MIF2), are overexpressed in almost all cancer types, and their high expressions are related to a worse prognosis for the patients. MIF is involved in 9 of the 10 hallmarks of cancer, and its inhibition by antibodies, nanobodies, or small synthetic molecules has shown promising results. Even though DDT is also proposed to be involved in several of the hallmarks of cancer, the available information about its pro-tumoral role and mechanism of action is more limited. Here, we provide an overview of the involvement of both MIF and DDT in cancer, and we propose that blocking both cytokines is needed to obtain the maximum anti-tumor response.
Funder
Research Foundation - Flanders
Reference168 articles.
1. Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium;Falzone;Front. Pharmacol.,2018
2. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations;Seidel;Front. Oncol.,2018
3. Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails;Zhou;Front. Pharmacol.,2019
4. National Institutes of Health (NIH) (2022, November 07). Pembrolizumab, Available online: https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab.
5. National Institutes of Health (NIH) (2022, November 07). Nivolumab, Available online: https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献